Renovacor, Inc. RCOR
We take great care to ensure that the data presented and summarized in this overview for Renovacor, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in RCOR
Top Purchases
Top Sells
About RCOR
Renovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut.
Insider Transactions at RCOR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 01
2022
|
Rtw Investments, LP > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
3,000,803
-100.0%
|
-
|
|
Dec 01
2022
|
Magdalene Cook Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
669,356
-95.48%
|
-
|
|
Dec 01
2022
|
Magdalene Cook Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
147,083
+50.0%
|
-
|
|
Dec 01
2022
|
Wendy F Dicicco Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
23,129
-100.0%
|
-
|
|
Dec 01
2022
|
Wendy F Dicicco Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,329
+50.0%
|
-
|
|
Dec 01
2022
|
Joseph S Carroll Chief Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,195
-100.0%
|
-
|
|
Dec 01
2022
|
Marc Semigran Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
52,651
-100.0%
|
-
|
|
Dec 01
2022
|
Marc Semigran Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,226
+50.0%
|
-
|
|
Dec 01
2022
|
Matthew Killeen Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,275
-100.0%
|
-
|
|
Dec 01
2022
|
Gbolahan Amusa Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
278,588
-100.0%
|
-
|
|
Dec 01
2022
|
Edward J. Benz Jr Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,586
-100.0%
|
-
|
|
Dec 01
2022
|
Edward J. Benz Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,586
+50.0%
|
-
|
|
Dec 01
2022
|
Jonas Grossman Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
394,657
-100.0%
|
-
|
|
Apr 22
2022
|
Jonas Grossman Director |
BUY
Other acquisition or disposition
|
Direct |
354,657
+36.3%
|
-
|
|
Apr 22
2022
|
Jonas Grossman Director |
SELL
Other acquisition or disposition
|
Indirect |
1,605,661
-100.0%
|
-
|
|
Apr 22
2022
|
Gbolahan Amusa Director |
BUY
Other acquisition or disposition
|
Direct |
238,588
+33.24%
|
-
|
|
Feb 01
2022
|
Jonas Grossman Director |
BUY
Other acquisition or disposition
|
Direct |
40,000
+50.0%
|
-
|
|
Feb 01
2022
|
Gbolahan Amusa Director |
BUY
Other acquisition or disposition
|
Direct |
40,000
+50.0%
|
-
|
|
Jan 24
2022
|
Matthew Killeen Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,275
+50.0%
|
-
|
|
Jan 24
2022
|
Magdalene Cook Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
70,825
+11.94%
|
-
|